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The aim of the present study was to evaluate the role of a weekly preoperative chemotherapy in locally advanced, unresectable
gastric cancer. In all, 82 patients with an Eastern Oncology Cooperative Group PS p2 and normal cardiac function were enrolled
onto the study. Surgical unresectability was confirmed in 52 patients (63%) at laparotomy, and in 30 (27%) cases by CT scan of the
abdomen and endoscopic ultrasonography. Chemotherapy treatment was: cisplatin 40mgm
 2; 5-fluorouracil 500mgm
 2;
epidoxorubicin 35mgm
 2; 6S-leucovorin 250mgm
 2 and glutathione 1.5gm
 2 (PELF). One cycle consisted of 8 weekly treatments.
Response to chemotherapy was observed in 40 of 82 patients (49%): six (7%) complete and 34 (41%) partial responses, and in four
(5%) cases a complete pathological response was confirmed. Of the 40 responding patients, 37 (45%) had potentially curative
surgery. Grade 3/4 leucopenia and thrombocytopenia occurred in three and two patients. At a median follow-up of 48 months, 25 of
the 37 resected patients (68%) were alive and 24 (65%) were disease free. The median and 4-year survival for the whole group was
17 months and 31%, respectively. The median survival was 12 months for inoperable patients and it was not reached in resected
patients.
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Although the incidence of gastric cancer has gradually decreased in
many Western Countries, it remains one of the leading causes of
cancer-related deaths worldwide, and it now ranks second only to
lung cancer with about 755000 new cases per year (Karpeh et al,
2001). Since screening for early detection is not performed in
Western Countries, in approximately 50% of newly diagnosed
cases, the tumour is beyond its local–regional margins (Kelsen,
1996; Karpeh et al, 2001). Surgery remains the mainstay of any
curative treatment, but only when a radical resection is feasible
(removal of all gross cancer cells at the resection margins as
determined by histopathological examination). Those patients who
are considered not amenable of curative resection generally receive
chemotherapy in order to obtain palliation of symptoms and
improved survival. Since there is no evidence that a more
aggressive treatment could result in a better survival, most of the
patients receive a combination of 5-fluorouracil (5-FU), mitomycin
C or cisplatin (Karpeh et al, 2001). Only a few studies have focused
on the role of preoperative chemotherapy in unresectable gastric
cancer. Comprehensively, these trials suggested that chemotherapy
could allow radical surgery in approximately 40% of all cases not
amenable of curative resection at presentation, but at the cost of
severe toxicity (Kelsen, 1996). In a pilot trial, we observed that a
preoperative chemotherapy with weekly cisplatin (CDDP), epidox-
orubicin (epi-ADR), 5-FU, 6S-leucovorin, glutathione and bone
marrow support (filgastrim) could allow a radical resection in 13
out of 32 (41%) patients previously considered unresectable
(Cascinu et al, 1998). These encouraging findings followed our
demonstration of activity (62% overall response rate in 105
patients) of this chemotherapy regimen in patients with advanced
gastric cancer. In this latter trial, five of 11 (45%) patients with
exclusively locally advanced unresectable disease could undergo a
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lcurative resection after chemotherapy (Cascinu et al, 1997). In
order to test whether the hypothesis of a more aggressive and
expensive approach in this subset of gastric cancer patients could
be justifiable, we prospectively analysed the effects of this intensive
weekly treatment in a larger group of gastric cancer patients not
amenable of curative resection.
MATERIALS AND METHODS
Patients’ selection
Patients with previously untreated, histologically confirmed,
locally confined, gastric adenocarcinoma were eligible for the
study, only after the primary tumour was considered not amenable
of surgical resection. Unresectable disease was defined jointly by a
medical oncologist, a gastroenterologist and an abdominal surgeon
on the basis of the laparotomy findings and/or CT scan images
(tumour size 47cm, invasion of adjacent structures, such as
pancreas, omentum, aorta, oesophagus, liver), endoscopy and
endoscopic ultrasonography (EUS). Patients with distant, liver and
peritoneal metastases were excluded. The American Joint Com-
mittee on Cancer staging system (6th edition) was applied. Patients
were also required to have an Eastern Oncology Cooperative
Group (ECOG) performance status p2, an adequate hepatic
(serum bilirubin o1.5mgdl
 1), renal (serum creatinine
o1.5mgdl
 1) and bone marrow function (white blood cell
(WBC) 44000 cellsml
 1 with an absolute granulocyte count
41500 cellsml
 1, platelet count 4100000 cellsml
 1) and aged
between 18 and 70 years. As a potential cardiotoxic drug (epi-
ADR) was included in the chemotherapy regimen, patients with a
New York Heart Association class 42 were excluded from the
study. Pretreatment assessment included complete blood cell count
with WBC differential and platelet count, biochemical screening
profile, serum creatinine and/or creatinine clearance, CT scan or
radiograph of the chest, CT scan of the abdomen, endoscopy and a
bone scan. Gated pool scan was not routinely performed unless the
patient had a history of cardiac disease, in which case it was
mandatory and the patient was ineligible for the study if the left
ventricular ejection fraction was o45%. The protocol was
approved by the institutional review board, and all patients gave
informed consent, which indicated that they were fully aware of the
investigational nature of the study itself.
Chemotherapy
All patients underwent chemotherapy according to the weekly
PELF regimen, which consisted of a once a week administration of
CDDP 40mgm
 2 as a 30min infusion in 250ml of normal saline,
5-FU 500mgm
 2 as a 15min infusion in 100ml of normal saline
and epi-ADR 35mgm
 2 by intravenous bolus injection. A dose of
250mgm
 2 of 6S-stereoisomer of leucovorin as a 4h infusion in
250ml of normal saline was administered concurrently with
hydration and glutathione 1.5gm
 2 in 100ml of normal saline
over 15min, which was infused before each cisplatin administra-
tion in order to prevent CDDP-related neurotoxicity (Figure 1).
Antiemetic treatment with dexamethasone 20mg and ondansetron
8mg both given intravenously was administered, respectively, 45
and 15min before CDDP infusion. At 2h before CDDP adminis-
tration, patients received intravenous hydration with 1500ml of
normal saline plus 20mEq of potassium chloride and 15mEq of
magnesium sulphate. Intravenous fluids administration proceeded
for 2h after CDDP with 1000ml of normal saline. All patients
received filgastrim 5mgkg
 1 by subcutaneous injection from the
day after to the day before each chemotherapy administration. One
cycle of chemotherapy consisted of 8 weekly chemotherapy
administrations. Patients only received 8 weeks of treatment
(one cycle). In the event of toxicity, chemotherapy administration
was delayed by a week or until full recover in case of WBC count
o4000 cellsml
 1, platelet count o100000 cellsml
 1 or if grade 2
and 3 mucositis and diarrhoea occurred. The criteria for patient
withdrawal from study were patient’s refusal, tumour progression
and any grade 4 toxicities. Chemotherapy was administered as an
outpatient procedure in all cases. The planned delay between the
last week of treatment and surgery was 6–8 weeks.
Evaluation of response and toxicity
Objective response to chemotherapy was assessed after 8 weeks of
therapy, combining findings from both CT scan of the abdomen
and endoscopy, including a new biopsy of the tumour, if still
visible, or a biopsy of the area originally involved by the tumour.
Endoscopy and endoscopic ultrasonography was performed when
clinically indicated. Partial response (PR) was defined as having
both CT scan evidence of PR, according to the World Health
Organisation (WHO) criteria, and endoscopy showing a 450%
reduction of the visible tumour, or complete disappearance of the
tumour, but positive histology on biopsy of the previously
involved area. Complete response (CR) was defined as a complete
disappearance of the tumour as seen by CT scan of the abdomen
and a complete resolution of the endoscopic findings without
histological evidence of neoplastic cells on biopsy of the original
site of the tumour. Toxicity was evaluated weekly according to the
National Cancer Institute Common Toxicity Criteria (NCICTC).
The decision to perform a laparotomy with the aim of a radical
excision was evaluated each time a complete removal of the
tumour was jointly judged feasible by a medical oncologist, a
gastroenterologist and an abdominal surgeon.
RESULTS
In all, 82 patients were enrolled onto this study by coinvestigators
from seven Italian centres. The median age at diagnosis was 57
years (range 29–68 years); 57 (69.5%) patients were male and 25
(30.5%) were female, most of the patients enrolled were in good
general condition as PS (ECOG) was 0–1 in 72 (88%) patients and
two in the remaining 10 (12%) patients. The primary tumour was
located in the body of the stomach in 40 (49%) cases, in the gastro-
oesophageal junction in 18 (22%) cases, in the distal stomach in 18
(22%) cases and in the proximal stomach in six (7%) cases. In all,
52 (63%) patients underwent laparotomy, as a part of a failed
attempt at radical primary surgery, before study entry, in these
cases laparotomy confirmed the presence of locally advanced,
unresectable disease, whereas in the remaining 30 (37%) patients
the diagnosis of locally advanced disease was confirmed by CT
scan of the abdomen (23 patients) and EUS (seven patients). All
patients received eight weekly treatments (one cycle of chemother-
apy). Patient characteristics are summarised in Table 1.
We observed a response to chemotherapy in 40 of 82 patients
(49%), six (7%) patients had a CR and 34 (41%) had a PR. Of these,
30 (36%) patients showed disease stabilisation, whereas 12 (15%)
patients progressed on chemotherapy. Among the 40 responding
patients, 37 (45%) had potentially curative radical surgery and
three (4%) were found not resectable at laparotomy. In four (5%)
Day 1 
PELF
Day 8 Days 2 − 7
Filgastrim 5 g kg−1
Days 9 − 14 Day 15
PELF PELF
Filgastrim 5 g kg−1
Figure 1 Diagram showing the treatment given in the first 2 weeks of
therapy. The same treatment schedule was administered for 8 consecutive
weeks.
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lcases, a complete pathological response was confirmed (Table 2).
Among the 37 patients who received radical surgery after
chemotherapy, 16 (50%) had a failed initial laparotomy. At a
median follow-up from the start of the treatment of 48 months
(range 30–60 months), 25 of the 37 resected patients (68%) were
alive and 24 (65%) were disease free, the 4-year survival rate for
the whole group was 31%. The median survival was 17 months for
the whole group and 12 months for inoperable patients, while it
was not reached in resected patients (Figure 2). There were no
deaths associated with chemotherapy or major surgical complica-
tions in this study and the toxicity profile was globally acceptable.
We observed mainly haematological toxicities of grade 2:
leucopenia and thrombocytopenia in five and six patients,
respectively, while grade 3–4 haematological toxicities were rare
events (three cases of grade 3–4 leucopenia and two cases of grade
3–4 thrombocytopenia). Nonhaematological toxicities were un-
common and moderate (Table 3). Dose delays and dose reductions
were applied in 25 (30%) and seven (8.5%) patients, respectively.
No unplanned admissions were required at any stage during the
course of chemotherapy. All patients considered suitable for
surgery after chemotherapy underwent laparotomy within 6–8
weeks (median 48 days) from the end of chemotherapy,
accordingly to what was originally planned in the protocol. The
median hospital stay for surgery was 10 days (range 8–20 days),
accordingly to what was expected. We did not observe relevant 30-
day medical or surgical complications and no patients required
return to operating Theatre.
DISCUSSION
Advanced gastric cancer patients are a heterogeneous population
and at least two different clinical conditions should be considered
if the best treatment approach is to be defined. Patients with
metastatic tumours often present in poor general conditions and
with several disease-induced symptoms. In this subset of patients,
a palliative treatment is a reasonable option and a careful
Table 1 Patient characteristics
No of patients 82
Age (years)
Median 57
Range 29–68
Sex
Male/female 57/25
PS (ECOG)
03 9
13 3
21 0
Sites of primary tumor
Gastro-oesophageal junction 18
Proximal stomach 6
Body 40
Distal stomach 18
Initial stages
T4 N0 M0 13
T4 N1-2 M0 51
T3 N1-2 M0 18
Laparotomy
Yes 52
No 30
COG¼Eastern Oncology Cooperative Group.
Table 2 Stage at surgery (37 patients)
Stage Patients
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pT1N0 1
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PT3N0 12
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PT3N1 13
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Figure 2 (A) Kaplan–Meier overall survival (OS) curve for the whole
group of 82 patients. (B) Kaplan–Meier survival curves for patients who
underwent curative resection of primary gastric tumour after chemotherapy
(resected, - - - - - ), and for not resected patients (not resected, ——— ).
Table 3 Treatment toxicity (NCICTC): worst toxicity per patient
Grade I Grade II Grade III Grade IV
Leucopenia 6 5 2 1
Thrombocytopenia 5 6 1 1
Anaemia 5 3 2 —
Mucositis 4 3 — —
Diarrhoea — 2 — —
Nausea/vomiting 6 10 1 —
Neurotoxicity 1 2 — —
NCICTC¼National Cancer Institute common toxicity criteria.
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levaluation of the therapy-related toxicity is of primary relevance in
the selection of the appropriate chemotherapy regimen. On the
other hand, many patients present with a locally advanced disease
not amenable of a radical resection, but without metastatic
involvement of distant sites. These patients are reported to have
a longer survival and a globally better prognosis (Lowy et al, 1999;
Yano et al, 2002). Furthermore, they are potential candidates for a
treatment with curative intent, as an objective response to
chemotherapy may allow a radical resection of the tumour. In
these latter cases, an active chemotherapy regimen should be
preferred even when this implies a greater risk of moderate–severe
toxicity.
We investigated the role of an intensive weekly chemotherapy
regimen in 82 patients diagnosed with unresectable gastric cancer.
The overall response rate to chemotherapy in our series was 49%
(40 of the 82 patients), which compares well to that achievable with
other active chemotherapy regimens available (Findlay et al, 1994;
Louvet et al, 2002). However, the most interesting data arising
from our study is the curative resectability rate, which we obtained
in this particularly difficult setting of patients: in fact, 45% (37 of
the 82 patients) of all cases treated could undergo a radical
resection, a procedure that was excluded at presentation. More-
over, the 4-year survival rate of the resected group was definitely
higher (68%) compared to that achieved by the whole group
(31%). These data seem to confirm that complete resection of all
gross disease with negative margins on pathology examination
represents the only potentially curative therapy for gastric cancer,
and that a preoperative, effective, chemotherapy regimen might
probably improve the outcome of patients, who would have been
otherwise excluded from curative resection on the basis of initial
findings. The chemotherapy combination we used also showed a
favourable profile of toxicity, which was mild and quite acceptable.
Overall, only two cases of grade 4 haematological toxicity (one case
of leucopenia and one case of thrombocytopenia) were reported
and no surgical complications were observed in those who
underwent surgery. Other authors explored preoperative che-
motherapy in locally advanced gastric cancer patients with
contrasting results, basically depending on the patients’ population
investigated (resectable or not resectable at presentation) and the
chemotherapy regimen employed. The available data with the ECF
regimen (epi-ADR, cisplatin and 5-FU) in this setting are
disappointing. In a small trial by Melcher et al (1996), only one
of 10 patients found to have locally advanced, unresectable, disease
proceeded to radical surgery after ECF chemotherapy, and in a
more recent study other authors substantially confirmed the
findings previously reported by Melcher using the same regimen,
as none of the four patients with initially unresectable disease was
rendered resectable; moreover, none of them was alive at a median
follow-up of 30 months (Geh et al, 2000). Even though it is possible
that chemotherapy duration, 12 weeks as opposed to the 24 weeks
of the Royal Marsden Hospital’s experience, could have negatively
affected results, these data do not seem encouraging for further
studies in this group of patients. Interesting results have been
initially reported with the use of the FAMTX regimen (5-FU,
doxorubicin and methotrexate). In patients with high risk, but
potentially curable, gastric tumours, 34 of 56 patients (61%)
received a curative resection, but at the cost of substantial toxicity
(mainly neutropenic fever) with one chemotherapy-related death
(Kelsen et al, 1996). Nevertheless, data from a small randomised
trial that compared the use of FAMTX as preoperative therapy
before surgery vs surgery alone in operable gastric cancer could
not demonstrate that the FAMTX regimen was suitable as
neoadjuvant chemotherapy, and the authors concluded that more
active regimens should be tested in further randomised studies
(Songun et al, 1999). It should be noticed that in preoperatively
unresectable patients, a combination chemotherapy containing
methotrexate and 5-FU was reported by Plukker et al (1991) to
allow 40% of curative resections. In a further trial, 34 patients with
unresectable gastric cancer were treated with either of the two
neoadjuvant chemotherapies: FEMTXP (5-FU, epirubicin, metho-
trexate, cisplatin) or THP-FLPM (pirarubicin, 5-FU, leucovorin,
cisplatin, mitomycin C). Of 33 evaluable patients, only eight (24%)
curative resections could be performed; interestingly, at multi-
variate analysis salvage surgery was found to be the only
independent prognostic factor in this series (Yano et al, 2002).
The EAP regimen (etoposide, doxorubicin and cisplatin) obtained
more than 70% of curative resections in patients with high-risk,
locally advanced gastric cancer. Nevertheless, toxicity was
considerable and all cases were theoretically resectable at
presentation (Schuhmacher et al, 2001). Results with the same
regimen in not resectable cases are clearly less appealing and
approached a 44% of resectability rate (Wilke et al, 1990). A major
matter of debate in this area is also accurately defining
preoperative staging procedures. Although a correct diagnosis of
the extent of disease is of paramount importance in locally
advanced gastric cancer, standard techniques are still to be
defined. Direct vision by surgical exploration might represent
the best initial assessment available, but would significantly
contribute to increase treatment morbidity and might cause the
patients to undergo an unnecessary laparotomy. Laparoscopy, EUS
or a combination of these two techniques could complement
traditional staging methods and provide clinical data not otherwise
obtainable (Ajani et al, 1999). Demonstration exists that these
procedures can improve staging of the primary tumour and detect
unsuspected metastatic disease with interesting sensitivity and
specificity, thus allowing a better patient selection and confronta-
tion between different series. Particularly promising seemed data
with regard to the use of EUS in preoperative staging of stomach
tumours (Lightdale et al, 1989; Botet et al, 1991). Endoscopy and
endoscopic ultrasonography showed an accuracy of 75–85% in
predicting tumour stage before surgery, but its use in the
evaluation of response to treatment in patients, who received
preoperative chemotherapy, was disappointing and unreliable
probably due to chemotherapy-induced changes in the physical
pattern of the tumour (Kelsen et al, 1996; Ajani et al, 1999).
Nevertheless, before a more widely diffusion of these methods
occur, traditional procedures are to be applied in order to define
surgical resectability. CT scan proved to possess an accuracy of
80–90% in defining local diffusion in gastric cancers. Clear CT
scan signs of tumour extension to pancreas, aorta, omentum,
oesophagus and liver, and the presence of bulky tumour (47cm)
should discourage surgery, as initial treatment in these patients, as
the probability to obtain a radical resection is very low (Sussman
et al, 1988; Rougier et al, 1994). In our trial more than a half of the
patients were considered not resectable by direct surgical
exploration: in fact, 52 (63%) patients underwent laparotomy, as
a part of a failed attempt at radical primary surgery, before study
entry. In the remaining 30 (27%) patients, the diagnosis of locally
advanced disease was confirmed by CT scan of the abdomen (23
patients) and EUS (seven patients). These data demonstrate that in
our series preoperative tumour upstaging is unlikely to have
occurred, thus making our findings fully interpretable.
Chemotherapy with weekly CDDP, epi-ADR, 5-FU, 6S-leucov-
orin, glutathione and bone marrow support (filgastrim) seemed to
be highly effective in patients with locally advanced, unresectable,
gastric cancer, as it allowed a potentially curative resection in 45%
of the cases we observed. Moreover, even though the study design
could not allow any definitive conclusion, the median survival and
the 4-year survival time (68%) of the resected group were
suggestive of a survival advantage in this subset of patients
determined by the use of preoperative chemotherapy. These
findings are even more interesting when we consider the
favourable profile of toxicity and the short period of treatment
requested (8 weeks as opposed to 12–24 weeks of other
chemotherapy regimens). Taken together, the data obtained from
the present study suggest that this intensive weekly regimen could
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lrepresent a therapeutic option for patients with locally advanced,
unresectable, gastric cancer, with the aim to allow a curative
resection, and hopefully a prognostic improvement, in about half
of all cases. According to these findings, the PELF weekly regimen
has now become our standard ‘off-trial’ treatment for selected
cases, showing clinical characteristics similar to those outlined in
our protocol. However, in the daily clinical practice, this
chemotherapy regimen should not always be considered a possible
choice, especially for patients in poor general conditions, thus
making this treatment unsuitable for approximately 15–20% of all
cases. Further, well-designed randomised studies are clearly
warranted in order to confirm our findings. We believe that a
randomised clinical trial investigating the PELF weekly regimen
against a docetaxel-containing regimen, as proposed by Ajani et al
(2003),would be of particular interest in order to improve the
standard of care in this setting.
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